Market news

August J Troendle, President & CEO at Medpace Holdings (NASDAQ:MEDP), reported an insider sell on September 23, according to a new SEC filing. What Happened: Troendle's decision to sell 70,901 shares of Medpace

August J Troendle, President & CEO at Medpace Holdings (NASDAQ:MEDP), executed a substantial insider sell on September 21, according to an SEC filing. What Happened: Troendle's decision to sell 10,880 shares of

Medpace Holdings (MEDP) is back in focus as investors watch for its upcoming earnings report, with expectations for higher earnings per share and revenue shaping near term sentiment around the contract research group. Recent trading has been upbeat, with a 1-day share price return of 1.94%, a 7-day share price return of 4.84%, and a 90-day share price return of 31.83% lifting Medpace Holdings to US$624.20. That short term momentum sits on top of a 1-year total shareholder return of 25.32% and...

Medpace (MEDP) concluded the recent trading session at $624.2, signifying a +1.94% move from its prior day's close.

August J. Troendle, 10% Owner, Director, President & CEO, on September 17, 2026, sold 10,880 shares

In the latest trading session, Medpace (MEDP) closed at $595.41, marking a +1.34% move from the previous day.

Robert O. Kraft, Director, on August 26, 2026, sold 3,858 shares in Medpace Holdings (MEDP) for $2,3

Medpace currently trades at $610.21 and has been a dream stock for shareholders. It’s returned 238% since August 2021, more than tripling the S&P 500’s 70.1% gain. The company has also beaten the index over the past six months as its stock price is up 35.1% thanks to its solid quarterly results.

Medpace stock is back below a buy point of 628.92. The medical research contractor delivered an earnings beat for its second quarter.

Troendle retains a $3.27 billion combined stake, representing 19% of the market cap, with the majority of holdings controlled through Medpace Investors, LLC.

Medpace (MEDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.

In the past few days, Medpace Holdings reported Q2 results that exceeded analyst revenue expectations and raised its full-year revenue guidance. The company also delivered the fastest revenue growth and largest guidance increase among its peers, highlighting its current operational momentum within the sector. Next, we’ll examine how Medpace’s upgraded full-year revenue guidance may influence the existing investment narrative around growth sustainability. The latest GPUs need a type of rare...

Why Medpace Holdings Stock Is Back in Focus After Q2 Results Medpace Holdings (MEDP) drew fresh attention after reporting Q2 earnings that beat revenue expectations and came with a higher full year revenue outlook, alongside the strongest revenue growth and guidance raise among peers. See our latest analysis for Medpace Holdings. Medpace Holdings has seen its share price pull back slightly in the past week, although a 30 day share price return of 7.6% and a 90 day share price return of 37.8%...

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including Medpace (NASDAQ:MEDP) and its peers.

Drug Development Inputs & Services Stocks Q2 Recap: Benchmarking Medpace (NASDAQ:MEDP)

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Detailed price information for Iqvia Holdings Inc (IQV-N) from The Globe and Mail including charting and trades.

Revealing a significant insider sell on July 29, August J Troendle, President & CEO at Medpace Holdings (NASDAQ:MEDP), as per the latest SEC filing. What Happened: Troendle's recent move involves selling 7,238

Medpace Holdings demonstrates strong Q2 2026 net new business awards, with a 1.13x net book-to-bill and $3.0B backlog. Learn why MEDP stock is a buy.

In July 2026, Medpace Holdings reported second-quarter results showing year-over-year increases in revenue and net income, and subsequently raised its 2026 guidance to forecast total revenue of US$2.81 billion–US$2.89 billion and net income of US$494 million–US$514 million, alongside updated earnings per diluted share of US$17.25–US$17.95. The company also reported record net new business awards, a backlog of about US$3.00 billion, and completed a sizeable share repurchase program totaling...

Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Medpace says second-quarter earnings and revenue beat estimates, backed by stronger bookings, backlog growth and higher 2026 guidance.

Shares of clinical research company Medpace Holdings (NASDAQ:MEDP) jumped 14.4% in the afternoon session after the company reported second-quarter financial results that exceeded Wall Street's expectations. GAAP earnings per share came in at $4.25, surpassing analyst estimates of $3.99. Revenue reached $707.3 million, beating the consensus estimate of $689.7 million and marking a 17.2% increase year on year. Additionally, the company's adjusted EBITDA was $153.4 million, topping forecasts of $14